Observational Retrospective Cohort Study of Systemic Therapies for R/R DLBCL
Completed
- Conditions
- Diffuse Large B Cell Lymphoma
- Registration Number
- NCT04697160
- Lead Sponsor
- MorphoSys AG
- Brief Summary
To compare the efficacy outcomes of the L-MIND cohort with the effectiveness in a matched patient population treated with systemic NCCN/ESMO guideline listed regimens administered in routine clinical care.
- Detailed Description
This retrospective observational cohort study aims to generate a historical control consisting of R/R DLBCL patients who received currently guideline recommended therapies.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3573
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall Survival (OS) through study completion, an average of 1 year
- Secondary Outcome Measures
Name Time Method Overall/Objective Response Rate (ORR) through study completion, an average of 1 year Complete Response Rate (CR) through study completion, an average of 1 year Duration of Response (DoR) through study completion, an average of 1 year Time to next treatment (TTNT) through study completion, an average of 1 year Progression Free Survival (PFS) through study completion, an average of 1 year Treatment discontinuation rate due to adverse events through study completion, an average of 1 year Duration of treatment exposure through study completion, an average of 1 year Event Free Survival (EFS) through study completion, an average of 1 year
Trial Locations
- Locations (1)
MorphoSys Research Site
🇬🇧Westcliff-on-Sea, United Kingdom